R. Filshie

发表

domain mutations identify imatinib-treated patients with CML who have BCR-ABL kinase Real-time quantitative PCR analysis can be used as a primary screen to

R. Herrmann, P. Browett, A. Schwarer, 2012 .

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

R. Herrmann, P. Browett, A. Schwarer, 2004, Blood.

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

D. Zannino, J. Seymour, M. Hertzberg, 2017, Leukemia & lymphoma.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, T. Hughes, 2015, Leukemia & lymphoma.

Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

H. Nandurkar, T. Hughes, D. Yeung, 2015, International Journal of Hematology.

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near‐complete cytogenetic response to interferon‐α

A. Schwarer, T. Hughes, S. Branford, 2007 .

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

L. To, D. White, T. Hughes, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone

C. Tam, H. Nandurkar, S. Kamel, 2010, Leukemia & lymphoma.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

with for

Christopher, C. Tam, A. Schwarer, 2014 .

Delayed‐onset neutropenia associated with rituximab therapy

A. Grigg, F. Firkin, R. Filshie, 2003, British journal of haematology.

Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report

R. O'Day, R. Stawell, R. Filshie, 2022, Journal of Ophthalmic Inflammation and Infection.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

A. Schwarer, J. Seymour, D. White, 2018, Leukemia.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

J. Reynolds, A. Schwarer, Z. Rudzki, 2004 .

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

J. Reynolds, A. Schwarer, J. Seymour, 2005 .

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

M. Keating, C. Tam, M. Keating, 2014, Leukemia.

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

A. Bazargan, C. Tam, H. Prince, 2016, Leukemia & lymphoma.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

J. Reynolds, A. Schwarer, J. Seymour, 2008 .

Methaemoglobinaemia Produced by Phenazopyridine (Pyridium) in a Man with Chronic Obstructive Airways Disease

M. R. Lee, R. Filshie, T. Chakraborty, 1987, Scottish medical journal.

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four

M. Gandhi, I. Lewis, R. Hicks, 2015 .

Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

H. Nandurkar, Kah-Lok Chan, H. Quach, 2015, Leukemia & lymphoma.

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

A. Wei, J. Shortt, Marzia Rahman, 2022, Leukemia & lymphoma.

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

M. Dimopoulos, A. Palumbo, P. Sonneveld, 2014 .

Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation.

R. Filshie, 2002, Current pharmaceutical design.

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia

S. Jane, A. Wei, A. Bazargan, 2014, Blood Cancer Journal.

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

W. Pierceall, U. Oppermann, A. Roberts, 2021, Leukemia & lymphoma.

Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy

S. Opat, A. Bazargan, C. Tam, 2020, Leukemia & lymphoma.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

C. Tam, A. Schwarer, D. White, 2015, Blood.

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

G. Garcia-Manero, Jacqueline S. Garcia, U. Borate, 2021, Blood.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

L. Campbell, J. Reynolds, J. Szer, 2015, The Lancet. Haematology.

Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot

S. Kirsa, K. Thursky, M. Slavin, 2013, Internal medicine journal.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

J. Reynolds, J. Szer, C. Tiley, 2012, Blood.

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

M. Dimopoulos, A. Palumbo, P. Sonneveld, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

M. Gandhi, I. Lewis, R. Hicks, 2017, Haematologica.

Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone

H. Nandurkar, D. Clucas, R. Filshie, 2017, BMJ Case Reports.

All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 )

J. Reynolds, J. Szer, C. Tiley, 2012 .

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2010 .

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2011 .

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

C. Tam, M. Lasica, J. Butler, 2019, Leukemia & lymphoma.

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

A. Schwarer, D. White, T. Hughes, 2012 .

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

G. Garcia-Manero, Jacqueline S. Garcia, U. Borate, 2022, American journal of hematology.

VLA‐4 is involved in the engraftment of the human pre‐B acute lymphoblastic leukaemia cell line NALM‐6 in SCID mice

K. Bradstock, D. Gottlieb, R. Filshie, 1998, British journal of haematology.

therapy in acute promyelocytic leukemia (APML4) -retinoic acid, idarubicin, and IV arsenic trioxide as initial trans All-

J. Reynolds, J. Szer, C. Tiley, 2013 .

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

I. Kerridge, C. Tiley, S. Harrison, 2020 .

Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone

A. Wei, R. Filshie, E. Chew, 2007, Leukemia & lymphoma.

Lymphoma, a great imitator in neurology

T. Sutherland, P. Mckelvie, Subramanian Muthusamy, 2020, Journal of Clinical Neuroscience.

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Christina Brown, A. Enjeti, C. Cheah, 2021, Blood.

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

R. Filshie, Kenneth J C Lim, 2023, The Lancet. Haematology.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, S. Durrant, 2015, Leukemia & lymphoma.